WORLD NEWS
-
Revolution Medicines secures US$2B Royalty Pharma partnership to advance RAS-driven cancer therapies
This collaboration aims to support patients suffering from RAS-addicted cancers, a group of cancers driven by mutations in the RAS gene.
-
J&J launches first daily disposable multifocal contact lens for astigmatism
The new lens is intended for single-day use, offering a convenient and hygienic option for patients who have previously faced limited choices.
-
Harbour BioMed bags up to US$670M in autoimmune drug deal with Otsuka
Under the terms of the agreement, Otsuka will obtain exclusive global rights to develop, manufacture, and commercialize HBM7020 outside of Greater China.
-
Madrigal’s Rezdiffra nears historic European approval for MASH treatment
This recommendation is a crucial milestone, as no treatment for MASH is currently approved in the European Union.
-
Actio Biosciences raises US$66M to accelerate rare disease therapies
The capital raised will primarily support the development of Actio’s two lead oral drug candidates: ABS-1230 and ABS-0871.
-
Alvotech’s AVT06 nears European approval for Eylea biosimilar market
The approval of AVT06 follows a growing trend of biosimilars entering the market after Bayer’s patent expiry.
-
-
Siemens Healthineers partners with Massachusetts General Hospital to advance personalized cancer care with theranostics
Theranostics is a promising medical technique that uses one radiopharmaceutical to diagnose disease and a related therapeutic agent to treat it.
-
Health Canada approves Novartis’ Kisqali for high-risk early breast cancer
The new approval expands its use to earlier stages of the disease, aiming to reduce the risk of recurrence and improve long-term outcomes for patients.
-
Draig Therapeutics secures US$140M series A to advance neuropsychiatric therapies
The funding round was led by Access Biotechnology and attracted contributions from several prominent investors, including Canaan Partners, SR One, Schroders Capital, and Sanofi Ventures.